A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

Bristol-Myers Squibb369 enrolled

Overview

The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.

Study Type

OBSERVATIONAL

Enrollment

369

Conditions

Psoriasis

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Psoriasis (PsO) participants who received Deucravacitinib for the first time of the approved indications at medical institutions in Japan will be enrolled in this PMS Exclusion Criteria: * Participants receiving Deucravacitinib for an off-label indication will be excluded from this PMS.

Locations (1)

EP Pharmaline

Tosima-ku, Tokyo, Japan

Outcomes

Primary Outcomes

Incidence of Adverse Events (AEs)

Time frame: Up to 52 weeks

Secondary Outcomes

Proportion of participants achieving Static Physicians Global Assessment (sPGA) of 0/1 during study period

Time frame: Up to 52 weeks

Change from Baseline in Body Surface Area (BSA) during study period

Time frame: Up to 52 weeks

Proportion of participants achieving Global Improvement Score (GIS) during study period

Time frame: Up to 52 weeks

Distribution of demographic characteristics: Age

Time frame: Up to 52 weeks

Distribution of demographic characteristics: Sex

Time frame: Up to 52 weeks

Distribution of demographic characteristics: Height

Time frame: Up to 52 weeks

Distribution of demographic characteristics: Weight

Time frame: Up to 52 weeks

Distribution of demographic characteristics: Past history /complication

Time frame: Up to 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.